A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Summary
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last treatment.
Timeline
- Start
- 2010-06
- Primary completion
- 2013-06
- Completion
- 2014-05
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Armodafinil vs Placebo-First; p = 0.289; Wilcoxon (Mann-Whitney) NCT01160380 ↗
registry analysis (superiority or other test); Armodafinil vs Placebo-First; p = 0.954; Wilcoxon (Mann-Whitney) NCT01160380 ↗
registry analysis (superiority or other test); Armodafinil vs Placebo-First; p = 0.699; t-test, 2 sided NCT01160380 ↗
registry analysis (superiority or other test); Armodafinil vs Placebo-First; p = 0.636; Wilcoxon (Mann-Whitney) NCT01160380 ↗
registry analysis (superiority or other test); Armodafinil vs Placebo-First; p = 0.531; Wilcoxon (Mann-Whitney) NCT01160380 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Armodafinil | Small molecule | 150 mg | — |